United States Government Publishing Office publisher pbl distributor dst United States Government Accountability Office author aut Government Organization text government publication eng GAOREPORTS Legislative Agency Publications gao legislative 2010-08-12 U.S. Government Printing Office 2007-02-09 monographic deposited born digital 17 p. GA 1.13:GAO-07-481T https://www.govinfo.gov/app/details/GAOREPORTS-GAO-07-481T P0b002ee18038b5e2 f:d07481t DGPO 2010-08-12 2011-03-24 GAOREPORTS-GAO-07-481T machine generated eng fdlp REPORT GAOREPORTS-GAO-07-481T GAO-07-481T Beneficiaries Congressional oversight Medicaid Medicare Pharmaceutical industry Prescription drugs Prices and pricing Program abuses Program evaluation Executive agency oversight Transparency 340B Drug Pricing Program Medicaid Drug Rebate Program Medicare Part D Testimony A65744 Several federal programs help pay for or reduce the costs of prescription drugs for eligible individuals and entities. Three examples are the Medicaid drug rebate program, part of the joint federal-state Medicaid program that finances medical services for certain low-income people; the 340B drug pricing program, which provides discounted drug prices to certain eligible entities such as community health centers; and the Medicare Part D program, which provides a Medicare drug benefit for the elderly and certain disabled people. The price information drug manufacturers report under these federal programs affects related federal spending. Spending is also affected by the extent to which federal oversight ensures the accuracy of this information. GAO was asked to provide information related to the oversight of prescription drug pricing practices that affect these federal programs. This testimony focuses on the oversight of drug pricing related to the three programs and the implications for future congressional oversight. This testimony is based on recent GAO reports examining these programs and related work by the Department of Health and Human Services Office of Inspector General and others. https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-07-481T/html/GAOREPORTS-GAO-07-481T.htm https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-07-481T/pdf/GAOREPORTS-GAO-07-481T.pdf GAO-07-481T https://www.govinfo.gov/app/details/GAOREPORTS-GAO-07-481T Testimony GAO-07-481T; Prescription Drugs: Oversight of Drug Pricing in Federal Programs; Beneficiaries Congressional oversight Medicaid Medicare Pharmaceutical industry Prescription drugs Prices and pricing Program abuses Program evaluation Executive agency oversight Transparency 340B Drug Pricing Program Medicaid Drug Rebate Program Medicare Part D Volume 117 Page 2066 117 Stat. 2066 Volume 120 Page 4 120 Stat. 4 Public Law 108-173